Myleran (Busulfan)

Busulfan alkylates DNA, creating cross‑links that block replication and transcription. This damage triggers cell cycle arrest and apoptosis, especially in rapidly dividing cancerous and hematopoietic cells, thereby reducing disease burden and creating space for transplanted stem cells.

The dosing regimen for Myleran is individualized and determined by the prescribing physician based on the patient’s condition, body surface area, liver function, and treatment goals. Patients should follow the specific instructions provided by their healthcare professional.

Busulfan is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be avoided during pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug can be excreted in milk and may harm the infant.

To request Myleran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other alkylating agents such as cyclophosphamide, busulfan offers a distinct pharmacokinetic profile with a longer half‑life and a higher propensity for pulmonary and hepatic toxicity. Choice of agent depends on disease specifics, patient comorbidities, and transplant protocol preferences.

Myleran tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Myleran is supplied as oral tablets that are taken by mouth with water, usually on an empty stomach as directed by the treating physician. The exact schedule—single dose or divided doses—depends on the therapeutic plan and patient tolerance.

Serious risks include pulmonary fibrosis, hepatic veno‑occlusive disease, severe bone marrow suppression leading to pancytopenia, and seizures, particularly at high plasma concentrations. Patients should be monitored closely for respiratory symptoms, liver dysfunction, and blood count abnormalities.

Myleran is contraindicated in patients with known hypersensitivity to busulfan or any component of the formulation, in those with severe hepatic impairment, and in pregnant women unless the therapeutic benefit outweighs the potential fetal risk. Caution is also advised for individuals with pre‑existing lung disease.